de Sanjose Silvia, Holme Francesca
PATH, Seattle, USA.
PATH, Seattle, USA.
Papillomavirus Res. 2019 Jun;7:173-175. doi: 10.1016/j.pvr.2019.04.011. Epub 2019 Apr 16.
Effective screening for pre-cancerous lesions of the cervix is the only protective intervention that can be offered to women that have not had the opportunity to be vaccinated. Elimination goals are being developed so that by 2030, 70% of women aged 35-45 years should have been screened at least once in a lifetime and 90% of all detected lesions should have been treated. These goals focus on a substantial reduction of cervical cancer burden in low- and middle-income countries (LMICs). Scaling-up screening in these settings may be substantially improved by using self-sampling (SS), human papillomavirus (HPV) testing, and managing screened-positive women with accessible treatment. The implementation of these tools requires minimal health information data for traceability, provider training, community education, operational management and quality control. Cost-effective algorithms tailored to country needs can greatly impact the burden of disease in a limited number of years.
对子宫颈癌前病变进行有效的筛查是唯一能够为没有接种疫苗机会的女性提供的保护性干预措施。目前正在制定消除目标，以便到2030年，70%的35至45岁女性一生中至少接受过一次筛查，并且所有检测出的病变中有90%应得到治疗。这些目标侧重于大幅降低低收入和中等收入国家（LMICs）的宫颈癌负担。在这些环境中扩大筛查规模，可以通过使用自我采样（SS）、人乳头瘤病毒（HPV）检测以及为筛查呈阳性的女性提供可及的治疗来显著改善。实施这些工具所需的健康信息数据最少，用于可追溯性、提供者培训、社区教育、运营管理和质量控制。根据国家需求定制的具有成本效益的算法可以在有限的几年内极大地影响疾病负担。
